T1DM Patients With Active β-Cell Function Differ Immunologically

Share this content:
T1DM Patients With Active β-Cell Function Differ Immunologically
T1DM Patients With Active β-Cell Function Differ Immunologically

FRIDAY, June 30, 2017 (HealthDay News) -- Patients with remaining endogenous β-cell function after a decade of living with type 1 diabetes tend to have much higher levels of interleukin-35 (IL-35) than other patients with long-standing type 1 diabetes, according to a study published in the June issue of Diabetes Care.

Daniel Espes, M.D., of Uppsala University in Sweden, and colleagues reached their conclusions after studying 113 patients with type 1 diabetes. The disease duration of participating patients was 10 or more years.

The investigators found that approximately 40 percent of patients with type 1 diabetes and 10 or more years disease duration had measurable fasting C-peptide concentrations. The team also found that blood plasma IL-35 concentrations were noted to be twice as high in the patients with remaining C-peptide.

"Patients with remaining endogenous β-cell function after >10 years duration of type 1 diabetes differ immunologically from other patients with long-standing type 1 diabetes," the authors conclude. "In particular, they have a much higher IL-35 production."

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Global Prevalence of Insufficient Activity 27.5 Percent

Global Prevalence of Insufficient Activity 27.5 Percent

Levels of insufficient physical activity stable between 2001, 2016; increase seen in high-income countries

HTN Tx Intensification Common Upon Discharge in U.S. Vets

HTN Tx Intensification Common Upon Discharge in U.S. ...

Fourteen percent of older adults admitted to hospital for non-cardiac conditions had intensification of tx

Quarterly Canakinumab Reduces Risk for Gout Attacks

Quarterly Canakinumab Reduces Risk for Gout Attacks

Doesn't affect serum uric acid levels over time, but targets interleukin-1β

is free, fast, and customized just for you!




Already a member?

Sign In Now »